rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Metabolic effects of LYPLAL1 rs12137855-C were similar, but statistically less robust, to the effects of GCKR rs1260326-T. TM6SF2 rs58542926-T displayed opposite metabolic effects when compared with the fatty liver associations.
|
29648650 |
2018 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The presence of the minor PNPLA3 p.I148M risk allele increased the risk of developing NAFLD (OR = 3.29, P < 0.001) and was associated with higher steatosis, fibrosis, and serum CK18-M30 levels (all P < 0.05).
|
29483677 |
2018 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study.
|
29396131 |
2018 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The p.I148M variant leads to macrovescicular steaosis and predisposes to liver disorders from steatohepatitis to fibrosis.
|
30308089 |
2018 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Since DAG (FA18:1) has been implicated in hepatic insulin resistance, the unaltered proportion of DAG (FA18:1) in I148M PNPLA3 carriers with fatty liver may explain the normal insulin sensitivity in these subjects.
|
30227635 |
2018 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease.
|
30189691 |
2018 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although the PNPLA3 rs738409 G allele has been associated with the risk of steatosis in CHB patients, no association between this polymorphism and the risk of cirrhosis was seen.
|
29218813 |
2018 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PNPLA3 rs738409, GCKR rs780094 and TM6SF2 rs58542926 variants were independent risk factors of hepatic steatosis and elevated ALT levels.
|
29314568 |
2018 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
One year after LT, steatosis was present in 50.0% of homozygous recipients with the rs738409-G allele.
|
28718984 |
2018 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The PNPLA3 rs738409 GG donor genotype affects liver steatosis and steatohepatitis risk following living-donor LT.
|
28574625 |
2018 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This patient exhibited liver steatosis; he was neither diabetic, nor obese or alcoholic, but is a carrier of 2 polymorphisms, p.Ile148Met (rs738409) and p.Glu167Lys (rs58542926) on PNPLA3 and TM6SF2 gene, respectively, previously shown to be associated with nonalcoholic steatosis and fibrosis evolution.
|
28711549 |
2018 |
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the TM6SF2 E167K variant promotes the development of steatosis, fibrosis and cirrhosis in patients with chronic hepatitis C. Conversely, this variant reduces circulating atherogenic lipid fractions.
|
28839198 |
2017 |
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The associations between the rs738409 PNPLA3 gene polymorphism and steatosis and advanced fibrosis were tested under a recessive inheritance model using logistic regression analysis, including age, gender, BMI, ethnicity/color, HOMA-IR, alcohol intake, HCV genotype 3, and the rs58542926 TM6SF2 gene polymorphism as covariates.
|
29258449 |
2017 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The PNPLA3 rs738409 GG genotype is positively associated with HS, while the IFNL3 rs 12979860 CC genotype may be negatively associated with HS, in Asian CHC patients.
|
28797039 |
2017 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, its association with non-invasive ultrasound- and magnetic resonance (MR)-based markers of liver fibrosis and steatosis, the enhanced liver fibrosis (ELF) score, liver biopsy, as well as rs738409 in PNPLA3, has not been elucidated in NAFLD, so far.
|
28914407 |
2017 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In children with NAFLD, the risk of severe steatosis is increased by SGA at birth, independent of and in addition to other powerful risk factors (insulin-resistance and I148M variant of the PNPLA3 gene).
|
28555633 |
2017 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Using a 443 patient training set, protein biomarker discovery was performed using the highly multiplexed SOMAscan<sup>®</sup> proteomic assay, a set of 19 clinical variables, and the steatosis predisposing PNPLA3 rs738409 single nucleotide polymorphism genotype status.
|
28266614 |
2017 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We determined the frequency of PNPLA3 (rs738409), CSPG3/NCAN (rs2228603), GCKR (rs780094), PPP1R3B (rs4240624), TM6SF (rs8542926), LYPLAL1 (rs12137855) and MBOAT7 (rs626283) by RT-PCR in 117 HIV-positive patients on cART and stratified participants based on their "controlled attenuation parameter" (CAP) into probable (CAP: 215-300 dB/m) and definite (CAP >300 dB/m) hepatic steatosis.
|
28594920 |
2017 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Associations between the rs738409 polymorphism of the PNPLA3 gene genotype GG and hepatic steatosis and advanced fibrosis were observed.
|
29258449 |
2017 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The genetic polymorphism I148M of the patatin-like phospholipase domain-containing 3 (PNPLA3) is associated with hepatic steatosis and its progression to steatohepatitis (NASH), fibrosis and cancer.
|
29116096 |
2017 |
rs738409
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Among 270 HBV-infected patients, concurrent fatty liver was found in 107 patients (39.6%) and was associated with metabolic risks, cirrhosis (P = 0.016) and PNPLA3 rs738409 CG/GG genotype (P = 0.002).
|
27547913 |
2017 |
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, the low-frequency E167K variant of TM6SF2 and rare mutations in APOB, which impair very low-density lipoproteins secretion, predispose to progressive fatty liver.
|
26409295 |
2016 |
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
|
26745555 |
2016 |
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The Glu167Lys (E167K) transmembrane 6 superfamily member 2 (TM6SF2) variant has been associated with liver steatosis, high alanine transaminase (ALT) levels and reduced plasma levels of liver-derived triglyceride-rich lipoproteins.
|
25893821 |
2016 |
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After adjustment for age, gender, body mass index and homoeostasis model assessment score, steatosis severity was independently associated with IL28B rs12979860 (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.55-0.86, P = 0.001) and PNPLA3 rs738409 (OR 1.84, 95% CI 1.46-2.83, P < 0.001), but not TM6SF2 rs58542926 (OR 1.48, 95% CI 0.82-2.69, P = 0.19).
|
26259026 |
2016 |